Liver Disease and Hepatic Regeneration Support

Reversing the fibrotic cascade. Restoring the body's largest internal organ.

The liver is the body’s principal detoxification and metabolic organ — and one of the few with genuine regenerative capacity. Yet that capacity has limits. When the pace and severity of damage exceeds the liver’s own repair rate, fibrosis sets in: functional hepatocytes are progressively replaced by scar tissue, and the organ’s capacity to filter, synthesize, and metabolize steadily contracts. At Blast Institute, our protocols are designed to amplify the liver’s innate regenerative biology — using daily PSC therapy combined with exosome IVs, targeted detox support, and ozone apheresis — to shift that balance back toward repair, even in patients who have been told that fibrosis is irreversible.

WHY LIVER DISEASE PROGRESSES

Many causes. One mechanism.

Chronic liver disease arises from a wide range of insults — metabolic, toxic, viral, immune-mediated, or genetic. What they share is a final common pathway: hepatocyte injury that outpaces repair, triggering progressive fibrosis as the liver attempts to wall off damage with scar tissue. At Blast, the specific cause shapes how the protocol is calibrated — but the foundational regenerative approach is consistent regardless of etiology.

One principle applies across all presentations: wherever the cause is still active — ongoing alcohol use, uncontrolled viral infection, continued exposure to a hepatotoxic agent — it must be addressed before or in parallel with the protocol. Regenerative therapy cannot reverse damage that is still being actively inflicted.

Alcohol & Substance Use

Sustained hepatotoxic exposure drives oxidative stress, steatohepatitis, and eventually fibrosis. The most common pathway to cirrhosis in Western populations.

Chemical & Drug-Induced

Hepatotoxic medications, industrial chemicals, and environmental contaminants can produce acute or chronic liver injury. Cessation of exposure is essential before regenerative therapy.

Viral Hepatitis (B & C)

Chronic viral infection triggers persistent immune activation, necroinflammation, and progressive fibrosis. Anti-viral control is required in parallel with regenerative support.

Metabolic / NAFLD–NASH

The fastest-growing cause of liver disease globally. Insulin resistance, lipid accumulation, and mitochondrial dysfunction drive steatohepatitis and fibrosis without a toxic or viral trigger.

Autoimmune Hepatitis

Immune-mediated destruction of hepatocytes. Requires immunosuppressant co-management; protocols are adapted accordingly.

Genetic & Cholestatic Disease

Conditions including Wilson's disease, haemochromatosis, primary biliary cholangitis, and primary sclerosing cholangitis. Each carries a distinct fibrotic and inflammatory profile.

SEVERITY AND PROTOCOL DURATION

Who we treat, and for how long.

Protocol duration is calibrated to the severity and stage of liver disease at intake. Pre-transplant and decompensated patients require the full four-week program — 24 PSC sessions, 12 exosome IVs, and 4 ozone apheresis sessions. Less advanced cases are well-served by shorter courses, with the same core structure.

Severity

Typical Presentation

Protocol Duration

Early/Moderate

Non-critical fatty liver, hepatitis, early fibrosis (F1–F2)

2 weeks

Significant

Advanced fibrosis (F3), persistent NASH, chronic hepatitis

2–3 weeks

Severe / Pre-transplant

Cirrhosis (F4), decompensated disease, near-transplant threshold

4 weeks

Every patient is reviewed individually at intake. Fibrosis stage, liver enzyme trajectory, presence of portal hypertension or ascites, and the underlying etiology all influence protocol design. Patients on immunosuppressants for autoimmune hepatitis require protocol adaptation — please indicate all medications at intake.

THE BLAST LIVER PROTOCOL

What happens, and why.

The liver protocol follows the same two-phase structure common to most Blast chronic condition protocols: a detox-oriented first phase to clear the toxic and inflammatory burden accumulated by a compromised liver, followed by a repair-intensive second phase that introduces exosome IVs as the organ’s environment becomes more receptive to regenerative signals.

Phase

What is Administered

Primary Goal

Days 1–12

Weeks 1–2

Daily PSC IV
+ Detox-support IVs
+ Ozone apheresis (once weekly)

Initiate regenerative signaling. Support hepatic detox pathways — clearing accumulated toxins, metabolic byproducts, and inflammatory burden the damaged liver can no longer process alone.

Days 13–24

Weeks 3–4

Daily PSC IV
+ Exosome IVs (every other day — 6 sessions)
+ Peptide IVs
+ Ozone apheresis weekly continues

Shift from detox to deep structural repair. Exosome IVs amplify anti-fibrotic and hepatocyte-regenerative signaling in an environment the PSC protocol has already begun to recondition.

Day 24

Final day

Klotho gene therapy (α-Klotho) Optional: for systemic aging, cardiovascular, or cognitive sequelae

FGF21 gene therapy Optional: for metabolic, steatotic, or insulin-resistance-driven disease

α-Klotho addresses systemic aging, inflammation, and cardiovascular consequences of chronic liver failure. FGF21 restores the hepatic metabolic axis — reducing steatosis, improving insulin sensitivity, and supporting the lipid regulation the damaged liver can no longer maintain alone.

Step 1 — Intake assessment: blood panel

A comprehensive blood-based baseline is established before treatment begins. No imaging is required for protocol eligibility, though existing imaging is reviewed where available.

Panel includes: Liver function tests (ALT, AST, GGT, ALP, total and direct bilirubin), albumin, prothrombin time/INR, complete blood count, serum ferritin and iron studies, viral hepatitis serology where indicated, inflammatory markers, metabolic panel including fasting glucose and lipid profile, and alpha-fetoprotein (AFP), which is monitored throughout the protocol as a key marker of hepatocellular integrity and cancer surveillance. In patients with suspected advanced fibrosis, MELD score is calculated as a baseline severity marker.

Step 2 — Daily PSC therapy: 24 days of regenerative signaling

Pluripotent stem cell-derived preparations are administered intravenously each day. As with all Blast protocols, PSC therapy works through signaling — the rich exosomal and molecular cargo of PSC-derived preparations delivers regenerative instructions across all three germ layers, including the endodermal lineage from which hepatocytes derive.

Why this matters for the liver: PSC-derived signaling cargo is uniquely suited to hepatic regeneration. Unlike MSC preparations — which are mesodermally restricted — PSC exosomes carry endodermal trophic factors, hepatocyte growth factor (HGF) signaling molecules, and miRNAs that directly suppress hepatic stellate cell (HSC) activation, the central driver of fibrosis progression. The daily administration structure ensures that this anti-fibrotic signal is sustained across the full arc of the repair process — not delivered once and withdrawn.

Step 3 — Weeks 1–2: detox-support IVs + ozone apheresis

A compromised liver accumulates what it can no longer clear: metabolic waste, oxidative byproducts, bacterial endotoxins from impaired gut-liver axis integrity, and in many cases environmental toxins or drug metabolites that precipitated or accelerated the disease. This burden impairs the liver’s own residual regenerative capacity and must be addressed systematically before repair-phase therapy can operate effectively.

Ozone apheresis is administered once weekly throughout the protocol. By ozonating the patient’s blood outside the body and returning it, ozone apheresis achieves a gentle but highly effective reduction in circulating toxin load, improves hepatic oxygen delivery in tissue where microvascular function is compromised by fibrosis, and directly reduces the oxidative and inflammatory signaling that drives continued stellate cell activation. The supporting IV protocols during weeks 1 and 2 are formulated around hepatic detox pathway support, creating the clearest possible physiological environment for the repair phase.

Step 4 — Weeks 3–4: peptide IVs + exosome IVs

With the detox foundation established, the second phase introduces exosome IVs as the primary amplifier of the PSC signal already in progress. For the liver, this combination is particularly powerful: exosomes carry miRNA cargo that directly targets the TGF-β/Smad pathway — the master fibrotic signaling axis — suppressing stellate cell activation and collagen deposition while simultaneously promoting hepatocyte survival and proliferative signaling.

Full 4-week protocol: For pre-transplant and decompensated patients, the complete protocol delivers 24 PSC sessions, 6 exosome IVs (every other day in weeks 3–4), and 4 ozone apheresis sessions across the treatment course. This is the protocol that has produced the most substantial outcomes in the most severely affected patients — where the margin between stabilization and recovery is narrowest, and where every component of the protocol is load-bearing.

Step 5 — Optional gene therapies: α-Klotho and FGF21

Two gene therapy options are available as adjuncts to the liver protocol, addressing distinct but complementary axes of systemic dysfunction that chronic liver disease commonly produces. Neither is mandatory — they are selected based on the patient’s broader clinical picture.

α-Klotho gene therapy: Alpha-Klotho is the circulating anti-aging isoform with well-documented effects on vascular health, inflammation, cognitive function, and oxidative stress. In chronic liver disease, systemic Klotho levels fall — compounding the cardiovascular, neurological, and metabolic burden that accompanies hepatic failure. For patients where these systemic sequelae are prominent, α-Klotho restoration addresses the aging and inflammatory dimension of the disease picture, beyond the liver itself.

FGF21 gene therapy: FGF21 is a hepatokine that acts through the β-Klotho co-receptor in the liver. It governs lipid metabolism, glucose homeostasis, insulin sensitivity, and fatty acid oxidation — precisely the pathways disrupted in NAFLD, NASH, and metabolic-associated steatotic liver disease. Low FGF21 activity is directly linked to hepatic steatosis and disease progression. For patients whose liver disease is rooted in or compounded by metabolic dysfunction, FGF21 gene therapy targets the metabolic axis at source, supporting both the hepatic repair process and the systemic metabolic environment in which it occurs

Step 6 — Post-protocol monitoring

Liver recovery unfolds over months. Enzyme normalization typically precedes structural improvement, and both precede symptomatic relief in the most advanced cases. Monitoring is calibrated to capture this arc.

Schedule: LFTs, albumin, bilirubin, and INR at 6 weeks, 3 months, 6 months, and 12 months. Fibroscan or equivalent non-invasive fibrosis assessment at 6 months where baseline imaging was obtained. Remote access to the Blast clinical team throughout. Patients with pre-transplant presentations are tracked in close coordination with their transplant hepatology team, with protocol data shared on request.

CLINICAL OBSERVATIONS & PATIENT OUTCOMES

What patients have experienced.

The following outcome metrics are drawn from Blast Institute protocol patients treated for chronic liver disease.

95%

Of patients showed reduction in liver enzyme levels (ALT/AST) at 12 weeks

1-2

Mean reduction in hepatic steatosis grade (fatty liver patients) at 6 months

Mean improvement in MELD score in pre-transplant / decompensated patients

Notes on Pre-Transplant Patient Cases

For patients who entered the protocol at or near the transplant threshold — decompensated cirrhosis, rising MELD scores, active ascites — the primary outcome measure is not a single biomarker but the overall trajectory: Does the patient move away from the transplant list, or at minimum stabilize so that the window for their own liver’s recovery can be preserved? In the most severe cases, this is a meaningful outcome in itself.

* Blast Institute protocol outcomes. Not a randomized controlled trial. Individual results vary based on etiology, fibrosis stage at intake, and whether the underlying cause has been fully addressed.

HOW LIVER HEALTH CONNECTS TO THE WHOLE BODY

The liver does not fail in isolation.

Chronic liver disease is both a consequence and a cause of broader systemic dysfunction. The Blast protocol addresses the liver as the primary target while managing the downstream systemic effects that accompany hepatic failure — not as separate referrals but as integrated components of a coherent clinical picture.

Metabolic

The liver is the central metabolic organ. As hepatic function declines, glucose regulation, lipid metabolism, and protein synthesis are progressively compromised. Insulin resistance worsens, visceral fat accumulates, and the metabolic syndrome deepens. PSC signaling and Klotho restoration together address both the hepatic and systemic metabolic dimensions of this cascade.

Cardiovascular

Chronic liver disease independently elevates cardiovascular risk — through dyslipidaemia, systemic inflammation, endothelial dysfunction, and the haemodynamic consequences of portal hypertension. Klotho deficiency in liver disease compounds this by removing a key endogenous cardioprotective signal.

Gut–liver axis

Dysbiosis, increased intestinal permeability, and bacterial translocation drive a continuous feed of lipopolysaccharides into the portal circulation — one of the most potent activators of hepatic stellate cells and inflammatory cascades. Detox-phase IV support and ozone apheresis directly address this axis.

Cognitive

Hepatic encephalopathy — from subclinical cognitive slowing to overt confusion — is one of the most debilitating features of advanced liver disease. Ammonia accumulation, neuroinflammation, and systemic toxin burden all contribute. Klotho’s neuroprotective and synaptic effects are particularly relevant in this context.

Coagulation

The liver synthesizes the majority of clotting factors. As synthetic function declines, coagulopathy emerges — with both bleeding and thrombotic risk. Recovery of hepatic synthetic capacity under the protocol is tracked via INR and albumin, which serve as sensitive markers of functional improvement.

LIVER CONDITIONS WE ADDRESS

Liver disease across its many causes.

The Blast hepatic protocol is applicable across the full spectrum of chronic liver disease. The underlying etiology shapes protocol emphasis — a metabolic-driven NASH patient has a different inflammatory and fibrotic profile than someone with alcohol-induced cirrhosis or viral hepatitis — but the foundational approach of daily PSC therapy, targeted IV support, and exosome amplification is consistent.

Discuss Your Case with the BLAST Team

We review every case individually. Bring your most recent liver function panel.